Labeling

CHPA appreciates the opportunity to provide information relevant to use of the term “natural” in food labeling, and believes that a formal definition will help to reduce consumer confusion and provide clarity to manufacturers and marketers making claims relying upon such a definition.

CHPA appreciates the opportunity to provide information on features to add and potential functionality improvements to make the Dietary Supplement Label Database a more useful tool for regulators, consumers, and other users of the database.

CHPA applauds FDA's efforts to amend labeling regulations for conventional foods and dietary supplements in order to provide updated nutrition information to consumers.

The Petitioners request that the Commissioner of Food and Drugs add a warning to the labeling of all nonprescription drug products containing an ingredient with “anticholinergic or histamine H1 inverse agonist effects” noting that the product can cause a confusional state.

CHPA requests that FDA publish a statement of enforcement policy expressly permitting manufacturers of single-ingredient acetaminophen OTC drugs subject to the ongoing internal analgesic, antipyretic, and antirheumatic monograph proceedings to including labeling on products that provide instructions for use in children aged six months to two years.

Enclosed are comments on "Guidance for Industry; Organ-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use - Labeling for Products that Contain Acetaminophen."

Personal Care Products Council and CHPA comments in response to FDA rule regarding labeling and effectiveness requirements for certain OTC sunscreen products.

CHPA strongly supports the unanimous votes by the advisory committees to add weight-based dosing directions to the existing age-based labeled dosing directions for children.